In addition, our proband was enrolled in a different study where a multi-gene panel testing for hereditary breast/ovarian cancer predisposition (including the following genes: ATM, BARD1,CDH1,CHEK2, PALB2, PTEN, RAD50, TP53, PIK3CA, RAD51D, RAD51C, PMS2, MLH1, MSH2, MSH6, XRCC2, NBN, NF1 and STK-11) was used to assess the mutational status of selected patients. The gene discussed is TP53; the disease is ovarian carcinoma.